Home » Stocks » Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc. (ENZN)

Stock Price: $0.162 USD 0.002 (1.25%)
Updated Oct 22, 2020 3:53 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 7.17M
Revenue (ttm) 61,000
Net Income (ttm) -1.07M
Shares Out 44.25M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend $0.12
Dividend Yield 74.07%

Stock Quote

Trading Day Oct 22, 2020
Last Price $0.162
Previous Close $0.160
Change ($) 0.002
Change (%) 1.25%
Day's Open 0.128
Day's Range 0.128 - 0.170
Day's Volume 62,220
52-Week Range 0.02 - 0.27

More Stats

Market Cap 7.17M
Enterprise Value 1.26M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.25M
Float 35.77M
EPS (basic) -0.03
EPS (diluted) -0.02
FCF / Share 0.18
Dividend $0.12
Dividend Yield 74.07%
Earnings Yield n/a
FCF Yield 109.47%
Payout Ratio n/a
Shares Short 157,472
Short Ratio 1.03
Short % of Float 0.44%
Beta 0.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 0.91
PS Ratio 117.53
PB Ratio 1.28
Revenue 61,000
Operating Income -1.06M
Net Income -1.07M
Free Cash Flow 7.85M
Net Cash 5.91M
Net Cash / Share 0.13
Gross Margin 339.34%
Operating Margin -1,736.07%
Profit Margin -1,745.90%
FCF Margin 12,865.57%
ROA -7.19%
ROE -12.15%
ROIC 153.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$16.00*
Low
16.0
Current: $0.162
High
16.0
Target: 16.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue0.216.928.388.3817.4631.1734.4942.6048.0797.87
Revenue Growth-97.01%-17.44%0.02%-52.01%-44%-9.63%-19.03%-11.38%-50.88%-
Gross Profit0.216.928.388.3817.4631.1734.4942.6048.0797.87
Operating Income-0.975.867.016.6410.8028.7918.16-3.97-16.46-0.58
Net Income-0.985.855.45-1.1321.6428.8018.15-2.78-20.76177
Shares Outstanding44.2244.2244.2244.2244.2044.1343.7846.7451.9158.47
Earnings Per Share-0.020.130.12-0.030.490.650.38-0.06-0.403.03
EPS Growth-8.33%---24.62%71.05%----
Dividend Per Share0.12-0.150.150.85-3.652.00--
Dividend Growth--0%-82.35%--82.5%---
Operating Cash Flow6.91-0.986.472.6014.6832.3414.018.45-12.7322.62
Capital Expenditures-----0.152.23-0.01-0.63-1.97
Free Cash Flow6.91-0.986.472.6014.6832.4916.248.44-13.3520.65
Cash & Equivalents5.456.507.487.6411.6734.566.52197323460
Total Debt-------116129134
Net Cash / Debt5.456.507.487.6411.6734.566.5280.89194326
Assets6.4815.519.5111.2722.8935.047.12200343489
Liabilities0.420.520.370.944.805.441.87122146157
Book Value6.0614.999.1410.3318.0929.605.2677.47197332
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Enzon Pharmaceuticals, Inc.
Country United States
CEO Andrew D. Rackear

Stock Information

Ticker Symbol ENZN
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: ENZN
IPO Date February 15, 1984

Description

Enzon Pharmaceuticals is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company was founded on September 17, 1981 and is headquartered in Cranford, NJ.